Compare FAF & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | IMVT |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.3B |
| IPO Year | N/A | N/A |
| Metric | FAF | IMVT |
|---|---|---|
| Price | $67.18 | $24.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $75.75 | $29.13 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 02-11-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 428.61 | N/A |
| EPS | ★ 4.65 | N/A |
| Revenue | ★ $7,087,600,000.00 | N/A |
| Revenue This Year | $19.04 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | ★ 20.70 | N/A |
| 52 Week Low | $53.09 | $12.72 |
| 52 Week High | $68.64 | $27.80 |
| Indicator | FAF | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 50.20 |
| Support Level | $62.58 | $23.90 |
| Resistance Level | $66.70 | $26.82 |
| Average True Range (ATR) | 1.80 | 1.18 |
| MACD | 0.49 | -0.20 |
| Stochastic Oscillator | 92.94 | 53.11 |
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.